Novel Biomarkers of Immune Toxicity from CAR-T Cell Therapy Using Ultrasensitive NULISA™ Proteome Technology

R. L. Kirkpatrick, Joanne C. Beer, Emily M. Blaum, Ajmal Mian, Manishkumar S. Patel, Akansha Jalota, Ishara S. Ariyapala, Qinyu Hao, Wei Feng, Xiao-Jun Ma, Yulin Luo, Brian T. Hill, Neetu GuptamedRxiv 2024 · DOI

TL;DR

Researchers used an ultrasensitive proteomic platform (NULISA™) to map the "proteomic evolution" of patients undergoing CAR T-cell therapy, identifying a distinct temporal sequence of biomarkers for severe toxicity. The study reveals that severe side effects are not just characterized by early inflammatory spikes, but also by a late-stage failure of tissue repair and neuronal protection mechanisms.

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of B-cell malignancies, but it comes with a high risk of life-threatening toxicities: Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS).

While we know that "cytokine storms" drive these events, our current understanding is limited. Most clinical markers (like CRP or IL-6) are either too non-specific or appear too late to allow for proactive intervention. Furthermore, previous research has been hampered by "narrow-vision" protein panels that only look at a few dozen targets. This paper seeks to provide a high-resolution, longitudinal map of the systemic immune response to identify early warning signs and understand why some patients fail to recover properly from these inflammatory events.

Methods

The researchers employed NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay), a novel proteomic technology with attomolar sensitivity—orders of magnitude more sensitive than traditional ELISAs. This allowed them to simultaneously quantify 204 different inflammation-related proteins from tiny plasma samples.

The study followed a longitudinal design, collecting samples from 80 patients at six critical time points:

  1. Day of Apheresis (baseline, ~21 days before infusion)
  2. Day 0 (infusion)
  3. Days 1-2 (early initiation)
  4. Days 3-5 (peak expansion)
  5. Days 6-9 (peak toxicity)
  6. Days 11-16 (resolution/discharge)

They used linear mixed models to account for repeated measures and performed pathway enrichment and protein-protein interaction network analysis to see how these proteins "talk" to each other during the treatment course.

Datasets

The study utilized a cohort of 80 patients with relapsed/refractory Large B-cell Lymphoma (LBCL) treated with standard-of-care anti-CD19 CAR T-cells (e.g., Axi-cel, Tisa-cel). This represents one of the largest longitudinal proteomic cohorts for this therapy to date. Clinical data, including toxicity grading (ASTCT criteria), was maintained via a REDCap system.

Key Insights and Ideas

  • The Early Recruitment Phase: Within the first 48 hours—before major clinical symptoms often peak—severe toxicity was signaled by a specific trio of chemokines: CXCL1, CX3CL1, and CCL8. These act as "scouts," recruiting immune cells to the site of inflammation.
  • The Th2 Signature: The researchers detected significant increases in Th2 cytokines (IL-4, IL-5, and IL-13) in severe cases. These are notoriously difficult to detect with standard assays. Their presence suggests that the body is attempting tissue repair even as the inflammatory storm is raging, or that these pathways are contributing to the pathology of severe CRS.
  • Exhaustion as a Proxy for Toxicity: Markers usually associated with T-cell "burnout" or exhaustion (PD-1, CTLA-4, LAG-3) were significantly elevated in the circulation of patients with severe toxicity. This suggests that the massive over-activation of CAR T-cells leads to a rapid transition toward an exhausted state, which may simultaneously drive toxicity and limit long-term anti-tumor efficacy.
  • Failed Resolution: Perhaps the most striking finding was at the "resolution" stage (Days 11-16). Patients with severe toxicity showed significantly lower levels of growth factors (PDGFA, EGF) and the neuronal repair protein BDNF. This suggests that severe ICANS/CRS isn't just about "too much inflammation," but also a failure of the body's natural repair and neuroprotective mechanisms to kick in.

Key Results

  • Upregulation: 71 proteins were significantly upregulated in severe CRS, and 45 in severe ICANS.
  • Shared Markers: Consistent with prior work, IL-6, IFN-γ, and CCL2 were confirmed as core drivers, showing up to 4-fold increases at peak levels.
  • Network Density: Network analysis showed that the protein "interactome" in severe CRS is much denser and more interconnected than in ICANS, suggesting CRS is a more systemic, multi-pathway "storm," while ICANS may involve more specific cellular interactions.
  • Predictive Potential: The early elevation (Day 1-2) of CX3CL1 and TNF specifically in ICANS patients provides a potential window for neuro-specific prophylactic treatment.

Limitations and Future Work

While the cohort of 80 patients is robust for a proteomic study, the authors acknowledge the need for validation in even larger, multi-center cohorts. The study primarily identifies associations; further functional studies are needed to determine if these novel biomarkers (like BDNF or the Th2 cytokines) are merely "passengers" or active "drivers" of the toxicity.

Future work could involve using these early proteomic signatures to develop a "risk score" that clinicians could use to decide which patients should receive pre-emptive steroids or IL-6 blockers before severe symptoms even manifest.

Summary updated

Abstract

Abstract Translational relevance Using serial samples from patients undergoing anti-CD19 CAR T-cell therapy and NULISA TM , an assay with attomolar sensitivity, we identify novel plasma proteins associated with severe treatment-associated toxicities. This study not only reveals the evolution of proteomic biomarkers before and during therapy and their association with toxicities, it distinguishes between the induction and recovery phases, and provides insights into factors that may mediate chronic sequelae of CAR T-cell therapy. As the use of CAR T-cell therapy is limited by toxicities, especially in elderly patients or those with pre-existing comorbidities, being able to identify the patients who are at the highest risk for severe toxicities will allow for stratification strategies that would ultimately enable more widespread application of this cutting-edge therapy. Finally, this investigation reveals several potential therapeutic candidates to enable better management and pre-emptive mitigation of acute toxicities. Purpose The efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL) patients is limited by acute toxicities, most notably cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Previous biomarker studies have been constrained by narrow protein panels and limited time points. We employed NULISA TM , a novel ultrasensitive assay capable of simultaneously quantifying 204 proteins, to identify temporal proteome associations with acute toxicities in LBCL patients treated with anti-CD19 CAR T-cell therapy. Experimental Design Plasma samples from 80 LBCL patients who underwent anti-CD19 CAR T-cell therapy, collected before and after cell infusion, were analyzed with NULISA TM . Baseline demographics and treatment toxicities, including CRS and ICANS, were graded according to ASTCT consensus criteria. Differential protein abundance, pathway enrichment, and network analysis were performed. Results Our analysis revealed higher levels of the chemokines CXCL1, CX3CL1, and CCL8 associated with severe toxicity within the first two days of treatment. Thereafter, severe toxicity was marked by more abundant Th2 cell effector cytokines, IL4, IL5 and IL-13, markers of exhaustion, and TNF receptor superfamily proteins CTLA4, PDCD1, CD274, LAG3, TNFRSF1A, TNFRSF1B, and CD40. Finally, patients with severe toxicities showed lower levels of cell growth factors PDGFA and EGF, and the neuronal repair protein BDNF at the resolution stage. Conclusions This study represents the most comprehensive characterization of proteomic immune response to CAR T-cell therapy to date and identifies novel proteins, pathways, and networks associated with acute toxicity in the initiation and resolution phases, implicating them as potential biomarkers.
BibTeX
@misc{kirkpatrick2024novel,
  author = {R. L. Kirkpatrick and Joanne C. Beer and Emily M. Blaum and Ajmal Mian and Manishkumar S. Patel and Akansha Jalota and Ishara S. Ariyapala and Qinyu Hao and Wei Feng and Xiao-Jun Ma and Yulin Luo and Brian T. Hill and Neetu Gupta},
  title = {{Novel Biomarkers of Immune Toxicity from CAR-T Cell Therapy Using Ultrasensitive NULISA™ Proteome Technology}},
  year = {2024},
  doi = {10.1101/2024.12.18.24319239},
  howpublished = {medRxiv},
}
Figure